Added more this week. I really like the risk and reward ratio right now. As far as I can tell, the enrollment pause is going to be short. The product is promising and clearly advantageous over the competitions. The management team is strong. The risk of prolonged trial seems to be easing.
News 
Market Data 
Discover 
